Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
News 3/4/26
The telehealth urgent‑care market is hitting a wall as provider labor costs become effectively fixed by government regulation, while patient acquisition expenses continue to drain margins. Companies such as Keycare rely on health‑system referrals and Teladoc on insurer‑driven enrollment to offset acquisition costs, but these strategies are increasingly unsustainable. Competing niche models risk being squeezed out by larger players. A potential way forward is a hybrid approach—like the Hellocare concept—that combines hardware, automation, AI and remote clinicians to offload routine tasks from health‑system staff.
Unprecedented Wildfire Pollution Linked to Higher Stroke Risks
A retrospective registry analysis of the 2023 Canadian wildfire smoke event found that short‑term spikes in ozone and fine particulate matter (PM₂.5) were linked to a measurable rise in both the incidence and severity of strokes in Camden, New Jersey. Ozone...
STAT+: Virginia Lawmakers Push a New Approach to a Prescription Drug Affordability Board
Virginia lawmakers are proposing a prescription‑drug affordability board that will use Medicare’s annually negotiated drug list as its benchmark. The board would also impose upper payment limits, creating a ceiling on what insurers pay for those medicines. This strategy would...
Glen Tullman — Consumer-Directed Care and the Rise of AI-Powered WayFinding in Healthcare
Glen Tullman, CEO of Transcarent, says consumer‑directed care powered by generative AI is the next structural shift in a fragmented, costly health system. His WayFinding platform moves patients from simple search to agentic actions such as automated scheduling, symptom checking,...
Cigna CEO’s Departure Is The Latest Among Top Health Insurers
Cigna’s long‑time chief executive David Cordani announced his retirement, ending a 17‑year tenure and making way for COO Brian Evanko in July. His departure marks the fourth CEO exit among the nation’s top five health insurers within two years, underscoring...
Do We Have a Dunning Kruger Effect Problem in Healthcare AI?
The integration of AI tools such as large‑language models into clinical workflows is flattening the traditional Dunning‑Kruger curve, causing users of all expertise levels to overestimate their performance. Studies show modest performance gains but a larger perceived boost, a phenomenon...
Intralesional Cemiplimab Shows Promise as a Nonsurgical Alternative for Early-Stage CSCC
A phase‑1 pilot of low‑dose intralesional cemiplimab in early‑stage cutaneous squamous cell carcinoma (CSCC) demonstrated rapid tumor regression with visual objective response rates of 66.7%–75% and pathologic complete responses of 58.3%–66.7%. Safety was favorable, with no grade ≥ 3 events and minimal...
FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
The FDA has sent warning letters to 30 telehealth companies for falsely marketing compounded GLP‑1 products as equivalent to FDA‑approved drugs. The letters cite claims that obscure product sourcing and suggest the compounds are the same as regulated medications. This...
Varying Gaze Patterns Give Clues to Low Vision Rehab, Management
A new eye‑tracking study recorded how people with full sight, low vision, and blindness navigate a one‑mile urban route in New York City. The research found that walking speed declines with visual impairment while blind participants exhibit higher fixation rates...
Tirzepatide Delivers up to 21% Weight Loss, Dose‑dependent
Tirzepatide: In the SURMOUNT-1 trial, weight reduction percentages were dose-dependent: 5 mg: ~15.0% weight reduction. 10 mg: ~19.5% weight reduction. 15 mg: ~20.9% weight reduction (Jastreboff et al., 2022). https://www.nejm.org/doi/10.1056/NEJMoa2206038 https://www.gatlan.com/ @GatlanHealth 
Technimount Offers New Bracket for D-Size INOmax Gas Cylinder
Technimount has launched the Techni-INO, a crash‑tested bracket that securely holds D‑Size INOmax gas cylinders during EMS transport. The solution complies with SAE J3043 safety standards, reducing the risk of cylinders becoming projectiles in collisions or sudden stops. It incorporates...
The Future of Employer-Aligned DPC and Physician Autonomy
The article challenges the notion that Direct Primary Care (DPC) can thrive solely on individual consumer subscriptions, arguing that household‑income constraints limit universal demand. It highlights Bureau of Labor Statistics data showing modest health‑care spending capacity, especially for middle‑income families...
FDA Approves Navepegritide for Children With Achondroplasia
The FDA granted accelerated approval to navepegritide (Yuviwel), a once‑weekly CNP prodrug, for children aged two years and older with achondroplasia and open growth plates. In the phase 2b ApproaCH trial, the drug raised annualized growth velocity to 5.89 cm/year, a 1.49 cm/year...
Weighing Pros And Cons Of Prostate Cancer Blood Tests
A Super Bowl ad by Novartis promotes a finger‑free PSA blood test, emphasizing a painless alternative to rectal exams. PSA screening has been shown to reduce prostate cancer deaths, yet its high sensitivity also uncovers indolent tumors that may lead...
Cardiologists Perform First TAVR of Its Kind by Anchoring Valve to Crushed Stent
Interventional cardiologists performed the first ATLAS transcatheter aortic valve replacement, anchoring a Sapien 3 valve to a crushed Palmaz stent in a 75‑year‑old woman with severe non‑calcified aortic regurgitation and prior aortic dissection. The heart team selected the non‑coronary cusp for...
Surveys Show Differences in Patient, Clinician Perspectives on the Impact of Alopecia Areata
Cross‑sectional surveys of 225 clinicians and 522 patients reveal a stark mismatch in treatment priorities for alopecia areata. Clinicians rank rapid, near‑complete hair regrowth as the top goal, while patients place low‑risk safety profiles above speed. The data also show...
Harvard AI Doc on Why LLMs Can Be 'Uncomfortable' For Physicians and IT Leaders
Harvard researcher Dr. Adam Rodman warns that more than one‑third of U.S. adults are already turning to large language models like ChatGPT for medical advice, despite widespread gaps in digital health literacy. Many patients struggle to download their own records...
New Clinical Data Highlight Povorcitinib’s Potential to Achieve High-Threshold Lesion Clearance in HS
New post‑hoc analyses of the phase 3 STOP‑HS1 and STOP‑HS2 trials show that oral povorcitinib, a selective JAK1 inhibitor, delivers rapid, high‑threshold lesion clearance in patients with severe hidradenitis suppurativa. In the 75 mg arm, up to 57% of participants achieved complete...
Kyowa Kirin Abandons Touted Eczema Drug Following Safety Review
Kyowa Kirin announced it will cease all clinical trials of rocatinlimab, an anti‑OX40 antibody once touted as a potential eczema blockbuster, after a safety review identified emerging malignancy signals. The review, conducted with former partner Amgen, uncovered a confirmed and...
Hello Heart Announces Strategic Collaboration with American College of Cardiology
Hello Heart, a digital heart‑health platform, announced a strategic collaboration with the American College of Cardiology (ACC). The ACC will convene an independent clinician workgroup to evaluate Hello Heart’s monitoring technology, coaching tools, clinician reports, and EMR integrations. Hello Heart...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real‑world evidence from Duke’s PRECISION platform shows Pluvicto (Lu‑177 vipivotide tetraxetan) delivers a median progression‑free survival of 13.5 months in PSMA‑positive metastatic castration‑resistant prostate cancer (mCRPC) after androgen‑receptor pathway inhibitor (ARPI) therapy, matching the pivotal PSMAfore trial. Patients who received Pluvicto...
KeyCare Raises $27.4M to Scale Epic-Integrated Virtual Care Platform
KeyCare announced a $27.4 million financing round led by HealthX Ventures, bringing its cumulative capital to over $55 million. The Epic‑integrated virtual‑care platform connects health systems with independent providers across primary, behavioral, and urgent care. Funds will be used to scale operations,...
General Devices’ User Spotlight: Elgin, IL – Hospital Emergency Department Saves Thousands of Dollars on Forms
AMITA Health St. Joseph Hospital in Elgin, Illinois tackled chronic understaffing in its emergency department by adopting General Devices' GD Solution Suite. The digital platform replaced paper EMS forms, cutting the department’s annual form‑related expenses by $8,000. By eliminating lengthy...
Small Language Models Offer Efficient, Transparent Healthcare AI
Small language models (SLMs) are gaining attention in the generative AI field. SLMs are trained on relatively small amounts of data and have a relatively small number of parameters. SLM can be more practical than large language models as they are...
Pharma Pulse: FDA Grants Priority Review to Rusfertide and Expands Approval for Novo Nordisk’s Sogroya
The FDA granted priority review to Takeda’s rusfertide, a first‑in‑class hepcidin mimetic for polycythemia vera, after Phase III trials more than doubled response rates. A regulatory decision is expected in Q3 2026. The agency also expanded Novo Nordisk’s once‑weekly Sogroya to treat children...
Elsevier Expands ClinicalKey AI with Unrivaled Full-Text Knowledge Base and Technology Upgrades to Help Clinicians Make Decisions with Confidence
Elsevier announced major upgrades to ClinicalKey AI, adding full‑text content from more than 130 premium journals and leading medical societies such as The Lancet, NEJM, and the American College of Cardiology. The platform now offers real‑time traceability, linking each answer...
Fresenius Kabi Recalls Ivenix Infusion Pumps over Software Problem
Fresenius Kabi issued a Class I recall for its Ivenix large‑volume infusion pumps after a software flaw was discovered that misreports battery capacity and can freeze the user interface. The FDA linked the defect to two serious injuries reported in November,...
Boston Scientific Gets Farapulse Label Expansion in Europe
Boston Scientific’s Farapulse pulsed field ablation system received a CE‑mark label expansion in Europe, now covering persistent atrial fibrillation lasting at least seven days. The decision follows positive safety and efficacy data from the ADVANTAGE AF trial. The move mirrors...
One Foothold, 25 Million Victims: The Risk Inside Modern Breaches
Recent cyber incidents highlight how a single foothold can expose tens of millions of records. The Conduent Business Services breach grew to over 25 million victims, with attackers retaining access for nearly three months and exfiltrating 8.5 TB of data. Parallel attacks...
PHTI Evaluates Virtual GI Solutions: Clinical Outcomes and Cost Savings for IBS and IBD
The Peterson Health Technology Institute evaluated five virtual gastrointestinal platforms, separating them into wraparound and clinician‑led models. Wraparound solutions such as Cylinder and Digbi deliver nutrition and behavioral support that improve IBS symptoms and reduce commercial spending by $1,889 per...
FDA Drug Competition Action Plan
The FDA’s Drug Competition Action Plan (DCAP) continues to drive generic drug competition by streamlining standards for complex products, closing loopholes that allow brand‑name companies to delay approvals, and improving the overall ANDA review process. Aligned with GDUFA III, the plan...
Align Boards, Embrace Simplicity: Surviving Three Health Pivots
This week on Lifers, I interviewed @othman about how he navigated @color through three massive pivots—from cancer genetics to national COVID infrastructure and now a virtual cancer clinic. Timestamps: (00:00) Preview (00:58) Intro (01:03) Lessons from Figma and betting on the tortoise over the...
Prime Medicine Pursues Approval After Two-Patient Gene Editing Trial
Prime Medicine $PRME to seek approval for gene editing treatment after two-patient trial https://t.co/nBnrUzqSCN via @Jasonmmast
Nanocomposite Ag Nanoparticles Boost Anticancer Potential
Researchers have engineered a nanocomposite incorporating silver (Ag) nanoparticles that markedly improves anticancer efficacy. The hybrid material boosts reactive oxygen species generation and enhances tumor cell uptake while sparing normal tissue. In vitro studies show synergistic activity with standard chemotherapeutics,...
Pierre Fabre Pushes to Revive US Cell Therapy Approval
Pierre Fabre seeks to revive US approval chances for spurned cell therapy https://t.co/gJeklT8asd @ByJonGardner $ATRA $QURE $RGNX
FDA Guidance Boosts Biotech, HHS Calls It Fake
Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock https://t.co/IN9o4VIp03
At-Home Cervical Cancer Screening Wand Now Available In All 50 States
The FDA has approved the Teal Wand, the first at‑home cervical cancer screening device, now available nationwide for women ages 25‑65 at average risk. The wand collects a dry cervical sample at home, which is mailed to a lab for...
Gynaecology Data Gaps Sees Women’s Health Suffer
The Medical Technology Group’s new report reveals that 42 Integrated Care Boards (ICBs) lack basic data on gynaecology pathways, waiting times, diagnoses and outcomes. More than 750,000 women are currently waiting for hospital gynaecology services, yet most ICBs do not...
LLM Medical Research Overwhelmingly Lacks Real Clinical Data
A new systematic review of LLMs in medicine @NatureMedicine @ekoermann https://t.co/npvDeqUvel “Despite thousands [4,609] of publications since late 2022, only a small fraction use real clinical data and just 19 randomized trials exist.”
Ruxolitinib Cream Shows Strong Efficacy and Reassuring Safety in New Analyses
New integrated safety data from 20 trials confirm that ruxolitinib 1.5% cream delivers a low incidence of serious infections, cardiovascular events, thromboembolic events, and malignancies across atopic dermatitis, vitiligo and other inflammatory skin conditions. A phase 3b trial in adults with...
AI-Enabled Virtual HF Care May Help Boost GDMT, Stabilize Weight
A non‑randomized study of the ISHI Health AI‑enabled virtual heart‑failure platform showed significant gains in guideline‑directed medical therapy (GDMT) and improved weight stability among 747 patients across six community cardiology practices. The system collected remote biometric data, generated risk‑graded alerts,...
MedDream to Present AWS-Powered Imaging Viewer at HIMSS
MedDream will demonstrate its cloud‑native, AI‑ready universal DICOM viewer, built on AWS HealthImaging, at HIMSS 2026 in Las Vegas. The solution leverages AWS’s HTJ2K transfer syntax to stream large imaging datasets quickly and securely. It supports radiology, cardiology, ophthalmology, dental...
Newly Added Guidance Documents
The FDA has published a batch of newly added guidance documents, spanning drug exclusivity, post‑approval safety reporting, real‑world data studies, Bayesian trial methods, and patient‑preference research. Ten documents are highlighted, with six in draft form and four finalized, dated between...
Early Matrix Proteins Drive Kidney Fibrosis Dynamics
A new Nature Metabolism study identifies extracellular matrix protein ECM1 as a pivotal early regulator of kidney fibrosis. Global ECM1 knockout mice develop spontaneous fibrosis and premature death, while AAV9‑mediated ECM1 knockdown in fibroblasts markedly lessens fibrotic burden. Mechanistically, ECM1...
Pivot Point Consulting Partners With Microsoft Rural Health Resiliency Program for Dragon Copilot Deployment
Pivot Point Consulting has teamed with Microsoft’s Rural Health Resiliency Program to roll out the Dragon Copilot AI assistant to financially strained rural hospitals. Microsoft is providing a 60% discount off the standard price, while Pivot Point offers free readiness...
Demystifying the Smart Hospital at HIMSS26
Cleveland Clinic CIO Sarah Hatchett will lead a HIMSS26 panel that offers a practical roadmap for building new IT infrastructure and retrofitting existing hospital spaces to accommodate emerging technologies. The session targets health‑system leaders seeking concrete steps to transition toward...
Webinar: The Future Is Collaborative: Transforming Clinical Trials
A MEDSIR‑hosted webinar titled “The Future is Collaborative: Transforming Clinical Trials” examined how collaborative‑initiated trials and investigator‑initiated trials (IITs) are reshaping oncology research. Speakers Dr. Javier Cortés and Dr. Antonio Llombart‑Cussac, both leading breast‑cancer oncologists, discussed their roles in recent...
Bayesian Learning Uncovers Schistosomiasis Multimorbidity Risks
Researchers applied Bayesian machine‑learning to uncover risk factors for hepatosplenic multimorbidity in schistosomiasis. By fusing clinical records, environmental exposure data, and host genetic markers, the model pinpointed predictors such as specific immune‑gene variants and poor sanitation. Its capacity to continuously...
DarcyIQ Integrates with Epic and Athenahealth to Slash Admin Time
DarcyIQ, an AI‑powered revenue acceleration platform from Innovative Solutions, has launched native, HIPAA‑aligned integrations with Epic and athenahealth’s athenaOne using Model Context Protocol. The conversational layer lets clinicians and revenue teams interact with EHR data via natural language, eliminating platform...
MaxLife Technologies Inc. Dba Maxlife - 721453 - 02/20/2026
The FDA issued a warning letter to MaxLife Technologies for false and misleading claims on its website about compounded semaglutide and tirzepatide products. The company labeled the drugs as “generic compounded medication” and implied FDA approval and that MaxLife was...